Zimbabwe has rejected a major American healthcare agreement valued at 367 million US dollars (272 million pounds) spanning five years over the United States' insistence on sensitive data.
This move was revealed after a internal memorandum from December was disclosed, which showed President Emmerson Mnangagwa deemed the deal was "lopsided".
An official representative has since clarified that the United States was seeking health data for research and commercial purposes while was not willing to share the benefits from any future medical innovations.
"We must now begin the challenging and unfortunate task of winding down our health aid in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy indicated the US had furnished more than $1.9bn for health programmes to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has urged more negotiations to secure a agreement suitable to all parties so the country's vital HIV treatment initiative can continue.
Wider Background
This development follows a comparable situation in Kenya, where a court blocked a related deal with the US after concerns were raised about the safety of citizens' health data.
Since resuming office recently, US President Donald Trump has reduced foreign aid and closed the US Agency for International Development (USAID).
The agency had administered aid for the American government, but Trump stated its spending was "wasteful" and his government was seeking government-to-government agreements to boost openness and responsibility.
As per reports, Sixteen African countries have to date signed similar agreements, constituting more than $18.3bn of fresh investment.
Specifics of the Declined Agreement
This assistance for Zimbabwe would have supported "combating HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"We are confident this cooperation would have delivered extraordinary advantages for Zimbabwean communities, especially the 1.2 million men, women and children currently on antiretroviral therapy via US-supported programmes," the Ambassador added.
However, government spokesperson Nick Mangwana argued the arrangement was "unfair".
"The proposal required Zimbabwe to share its biological resources and data over an extended period, with no corresponding assurance of benefiting from any scientific breakthroughs – such as new medicines or tests – that could result from that provided information," his statement read.
"Put simply, our nation would supply the raw materials for medical research with no certainty that the resulting innovations would be accessible to our citizens if a future health crisis emerge."
National Interest and International Frameworks
He also said that the US's withdrawal from the global health body and its push of bilateral health agreements were disrupting systems previously set up through the international organization.
Mangwana gave as an example its Pandemic Benefit-Sharing system created to deal with potential pandemics.
"This framework is designed to ensure that when a nation provides its data, the benefits – including medicines and cures – are distributed fairly, not commercialised solely by those with the resources to create them."
These objections regarding the US deal "must not be interpreted as opposition to America," Mangwana stressed.
"We encourage continued discussions with our US partners on how future collaboration could be arranged in a manner that respects the sovereignty and interests of each country."
Health Experts Reaction
A leading public health body expressed it acknowledged the government's concerns, but suggested that talks need to persist since a large portion of the nation's HIV programmes relied on foreign aid.
"In cases where technical issues exist, such as those relating to information security or implementation frameworks, these can frequently be resolved via technical clarification and mutually agreed protections," the group added.
This impasse emphasises the continuing challenges between receiving vital foreign assistance and safeguarding local interests in an ever more data-driven world.